🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Single Vitamin and Mineral Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

100 mcg (83% DV)
✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.1mg
Calcium
50 mg (4% DV)

Other Ingredients

Dicalcium Phosphate Microcrystalline Cellulose Mannitol Stearic Acid Magnesium Stearate Croscarmellose Sodium

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Kosher Women (not pregnant or lactating)

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take one tablet daily.

⚠️ Warnings & Precautions

Keep out of reach of children.

Warning: Do not use if pregnant, nursing or are allergic or contraindicated to aspirin. If you are taking aspirin or blood thinning or other medication, consult your healthcare professional before using this product.

Discontinue use two weeks prior surgery, or if upset stomach occurs.

🧪 Formulation Notes

Helps the body transport calcium Involved in bone matrix formation

Vitamin K is necessary for blood clotting.

Potency verified by GNC procedure #5024. Conforms to USP <2091> for weight. Meets USP <2040> disintegration.

Ko (Kosher)

Additional Information

Store in a cool, dry place.

180-Day supply

Product Details

UPC / SKU 0 48107 20439 6
DSLD Entry Date 2020-05-22
Product Type Single Vitamin and Mineral
Form Tablet or Pill
Brand GNC
DSLD ID 219240
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →